Powering the Immune System to Transform Lives

Phil Pang photoPhil Pang, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

Phil Pang, M.D., Ph.D., has been with Vir since 2016 and currently serves as Executive Vice President and Chief Medical Officer, responsible for leading the Company’s global clinical development functions, including Clinical Research and Operations, Biometrics, Pharmacovigilance & Risk Management and Clinical Pharmacology, as well as overseeing the Company’s Medical Affairs division. Dr. Pang’s industry career has been dedicated to the development of novel therapies to address some of the world’s most challenging diseases.  

Prior to Vir, Dr. Pang served as Chief Medical Officer of Riboscience LLC, a Roche spinoff developing small molecule antivirals. Previously, during his tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrixed team to the successful worldwide approval of the first one-pill, once-a-day cure for hepatitis C.

Dr. Pang received a B.S. in biological sciences from Stanford University and a Ph.D. in biochemistry and biophysics from Columbia University. He obtained his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed his fellowship in infectious diseases and a post-doctoral fellowship in virology at Stanford University.